Patents by Inventor Elena Poggesi
Elena Poggesi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9889121Abstract: This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.Type: GrantFiled: March 13, 2017Date of Patent: February 13, 2018Assignee: Recordati Ireland Ltd.Inventors: Carlo Riva, Carlo De Toma, Patrizia Angelico, Elena Poggesi, Davide Graziani
-
Publication number: 20170182011Abstract: This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.Type: ApplicationFiled: March 13, 2017Publication date: June 29, 2017Inventors: Carlo Riva, Carlo De Toma, Patrizia Angelico, Elena Poggesi, Davide Graziani
-
Patent number: 9593127Abstract: This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.Type: GrantFiled: December 29, 2015Date of Patent: March 14, 2017Assignee: RECORDATI IRELAND LTD.Inventors: Carlo Riva, Carlo De Toma, Patrizia Angelico, Elena Poggesi, Davide Graziani
-
Publication number: 20160185798Abstract: This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.Type: ApplicationFiled: December 29, 2015Publication date: June 30, 2016Inventors: Carlo Riva, Carlo De Toma, Patrizia Angelico, Elena Poggesi, Davide Graziani
-
Patent number: 8518916Abstract: This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).Type: GrantFiled: August 4, 2008Date of Patent: August 27, 2013Assignee: Recordati Ireland LimitedInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi, Davide Graziani, Matteo Longhi
-
Publication number: 20100317630Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.Type: ApplicationFiled: February 4, 2010Publication date: December 16, 2010Applicant: RECORDATI IRELAND LIMITEDInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi, Davide Graziani
-
Publication number: 20090042841Abstract: This invention relates to novel heterocyclic compounds having selective affinity for the mGlu5 subtype of metabotropic receptors, pharmaceutical compositions thereof and uses for such compounds and compositions in the treatment of lower urinary tract disorders, such as neuromuscular dysfunction of the lower urinary tract, and in the treatment of migraine and gastroesophagael reflux disease (GERD).Type: ApplicationFiled: August 4, 2008Publication date: February 12, 2009Applicant: Recordati Ireland LimitedInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi, Davide Graziani, Matteo Longhi
-
Publication number: 20040215284Abstract: The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agent for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal.Type: ApplicationFiled: January 29, 2004Publication date: October 28, 2004Applicant: Recordati S.A.Inventors: Amedeo Leonardi, Rodolfo Testa, Elena Poggesi
-
Publication number: 20040072839Abstract: Described are novel 1-phenylalkylpiperazines having affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-piperazine oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor activity. Also described are the preparation of the compounds and the pharmaceutical compositions containing them.Type: ApplicationFiled: June 16, 2003Publication date: April 15, 2004Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
-
Patent number: 6680319Abstract: The invention relates to novel N-(substituted phenyl)-N′-[&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.Type: GrantFiled: January 17, 2002Date of Patent: January 20, 2004Assignee: Recordati S.A.Inventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
-
Publication number: 20020161012Abstract: The invention relates to novel N-(substituted phenyl)-N′-[(&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions. The compounds may be administered alone or in combination with an anticholinergic compound.Type: ApplicationFiled: January 17, 2002Publication date: October 31, 2002Applicant: RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANYInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
-
Patent number: 6365591Abstract: The invention relates to novel N-(substituted phenyl)-N′-[&ohgr;-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The compounds are endowed with enhanced selectivity for alpha1-adrenergic receptors and a low activity in lowering blood pressure. The compounds are useful in the treatment of obstructive syndromes of the lower urinary tract, including benign prostatic hyperplasia (BPH), and in the treatment of lower urinary tract symptoms (LUTS) and neurogenic lower urinary tract dysfunction (NLUTD), and other conditions.Type: GrantFiled: October 18, 2000Date of Patent: April 2, 2002Assignee: Recordati, S.A., Chemical and Pharmacueticals CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Elena Poggesi
-
Patent number: 6271234Abstract: Disclosed herein are novel compounds and methods for the treatment of disorders of the lower urinary tract. The novel compounds are 1,4-disubstituted piperazine derivatives. The methods comprise the administration of the novel compounds of the invention, and other compounds that bind to 5HT1A receptors, for treating disorders of the lower urinary tract.Type: GrantFiled: March 11, 1999Date of Patent: August 7, 2001Assignee: Recordati S.A., Chemical and Pharmaceutical CompanyInventors: Amedeo Leonardi, Gianni Motta, Carlo Riva, Luciano Guarneri, Elena Poggesi
-
Patent number: 4707497Abstract: A novel phenylethanolaminotetraline having lipolytic activity of formula ##STR1## wherin X represents hydrogen, halogen, a trifluoromethyl or a lower alkyl group and R represents hydrogen, a lower alkyl group not substituted or substituted by a cycloalkyl group containing 3 to 7 carbon atoms, a hydroxy group, a lower alkoxy, carboxy or lower carbalkoxy group; a cycloalkyl group containing 3 to 7 carbon atoms; or a lower alcanoyl group; or a pharmaceutically acceptable salt thereof; a process for its preparation; and pharmaceutical compositions containing it as active ingredient, useful for the treatment of obesity.Type: GrantFiled: July 10, 1986Date of Patent: November 17, 1987Assignee: SanofiInventors: Roberto Cecchi, Robert Boigegrain, Alberto Bianchetti, Elena Poggesi, Tiziano Croci